Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine

The Lancet Diabetes and Endocrinology

Volumn 7, Issue 1, 2019, Pages 65-74

  Roep, Bart O ^a,b   Wheeler, Daniel C S ^c   Peakman, Mark ^c,d  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUTAMATE DECARBOXYLASE 65; INSULIN; INTERLEUKIN 2; TRANSCRIPTION FACTOR FOXP3; AUTOANTIGEN;

AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DISEASE COURSE; DISEASE PREDISPOSITION; FEASIBILITY STUDY; FIRST PHASE INSULIN RESPONSE; GLUCOSE TOLERANCE TEST; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESPONSE; PANCREAS ISLET BETA CELL; PATHOGENESIS; PERSONALIZED MEDICINE; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; REGULATORY T LYMPHOCYTE; REVIEW; RISK FACTOR; T LYMPHOCYTE ACTIVATION; IMMUNOLOGY; PROCEDURES;

AUTOANTIGENS; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; INSULIN-SECRETING CELLS; PRECISION MEDICINE;

EID: 85058921914     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(18)30109-8     Document Type: Review

References (94)

1. Coppieters, KT, Dotta, F, Amirian, N, et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med 209 (2012), 51–60.
2. Leete, P, Willcox, A, Krogvold, L, et al. Differential insulitic profiles determine the extent of β-cell destruction and the age at onset of type 1 diabetes. Diabetes 65 (2016), 1362–1369.
3. Willcox, A, Gillespie, KM, Histology of type 1 diabetes pancreas. Methods Mol Biol 1433 (2016), 105–117.
4. Willcox, A, Richardson, SJ, Bone, AJ, Foulis, AK, Morgan, NG, Evidence of increased islet cell proliferation in patients with recent-onset type 1 diabetes. Diabetologia 53 (2010), 2020–2028.
5. Willcox, A, Richardson, SJ, Bone, AJ, Foulis, AK, Morgan, NG, Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol 155 (2009), 173–181.
6. Lampeter, EF, Homberg, M, Quabeck, K, et al. Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. Lancet 341 (1993), 1243–1244.
7. Stiller, CR, Dupre, J, Gent, M, et al. Effects of cyclosporin immunosuppresion in insulin-dependent diabetes mellitus of recent onset. Science 223 (1984), 1362–1367.
8. Keymeulen, B, Vandemeulebroucke, E, Ziegler, AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352 (2005), 2598–2608.
9. Herold, KC, Hagopian, W, Auger, JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes. N Engl J Med 346 (2002), 1692–1698.
10. Barrett, JC, Clayton, DG, Concannon, P, et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nature Genet 41 (2009), 703–707.
11. Koeleman, BP, Lie, BA, Undlien, DE, et al. Genotype effects and epistasis in type 1 diabetes and HLA-DQ trans dimer associations with disease. Genes Immun 5 (2004), 381–388.
12. Roep, BO, Kleijwegt, FS, van Halteren, AG, et al. Islet inflammation and CXCL10 in recent-onset type 1 diabetes. Clin Exp Immunol 159 (2010), 338–343.
13. Valle, A, Giamporcaro, GM, Scavini, M, et al. Reduction of circulating neutrophils precedes and accompanies type 1 diabetes. Diabetes 62 (2013), 2072–2077.
14. Bloem, SJ, Roep, BO, The elusive role of B lymphocytes and islet autoantibodies in (human) type 1 diabetes. Diabetologia 60 (2017), 1185–1189.
15. Arif, S, Leete, P, Nguyen, V, et al. Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes. Diabetes 63 (2014), 3835–3845.
16. Pescovitz, MD, Greenbaum, CJ, Krause-Steinrauf, H, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 361 (2009), 2143–2152.
17. Eizirik, DL, Miani, M, Cardozo, AK, Signalling danger: endoplasmic reticulum stress and the unfolded protein response in pancreatic islet inflammation. Diabetologia 56 (2013), 234–241.
18. Eizirik, DL, Colli, ML, Ortis, F, The role of inflammation in insulitis and β-cell loss in type 1 diabetes. Nat Rev Endocrinol 5 (2009), 219–226.
19. Bottazzo, GF, Death of a beta cell: homicide or suicide?. Diabet Med 3 (1986), 119–130.
20. Kronenberg-Versteeg, D, Eichmann, M, Russell, MA, et al. Molecular pathways for immune recognition of preproinsulin signal peptide in type 1 diabetes. Diabetes 67 (2018), 687–696.
21. Atkinson, MA, Roep, BO, Posgai, A, Wheeler, DCS, Peakman, M, The challenge of modulating β-cell autoimmunity in type 1 diabetes. Lancet Diabetes Endocrinol, 2018 published online Oct 24. http://dx.doi.org/10.1016/S2213-8587(18)30112-8.
22. Bougneres, PF, Landais, P, Boisson, C, et al. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 39 (1990), 1264–1272.
23. Harrison, LC, Colman, PG, Dean, B, Baxter, R, Martin, FIR, Increase in remission rate in newly diagnosed type 1 diabetic subjects treated with azathioprine. Diabetes 34 (1985), 1306–1308.
24. Eisenbarth, GS, Srikanta, S, Jackson, R, et al. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res 2 (1985), 271–276.
25. Orban, T, Bundy, B, Becker, DJ, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 378 (2011), 412–419.
26. Rigby, MR, DiMeglio, LA, Rendell, MS, et al. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol 1 (2013), 284–294.
27. Haller, MJ, Gitelman, SE, Gottlieb, PA, et al. Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes. J Clin Invest 125 (2015), 448–455.
28. Moran, A, Bundy, B, Becker, DJ, et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 381 (2013), 1905–1915.
29. Gitelman, SE, Gottlieb, PA, Rigby, MR, et al. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 1 (2013), 306–316.
30. Rigby, MR, Harris, KM, Pinckney, A, et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest 125 (2015), 3285–3296.
31. Hartemann, A, Bensimon, G, Payan, CA, et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 1 (2013), 295–305.
32. Todd, JA, Evangelou, M, Cutler, AJ, et al. Regulatory T cell responses in participants with type 1 diabetes after a single dose of interleukin-2: a non-randomised, open label, adaptive dose-finding trial. PLoS Med, 13, 2016, e1002139.
33. Larsson, HE, Lundgren, M, Jonsdottir, B, Cuthbertson, D, Krischer, J, DiAPREV-IT Study Group. Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: a randomized clinical trial. Pediatr Diabetes 19 (2018), 410–419.
34. Tavira, B, Barcenilla, H, Wahlberg, J, Achenbach, P, Ludvigsson, J, Casas, R, Intralymphatic glutamic acid decarboxylase-alum administration induced Th2-like-specific immunomodulation in responder patients: a pilot clinical trial in type 1 diabetes. J Diabetes Res, 2018 published online May 24. DOI:10.1155/2018/9391845.
35. Krischer, JP, Schatz, DA, Bundy, B, Skyler, JS, Greenbaum, CJ, Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: a randomized clinical trial. JAMA 318 (2017), 1891–1902.
36. Alhadj Ali, M, Liu, Y, Arif, S, et al. Metabolic and immune effects of immunotherapy with proinsulin peptide in new-onset human type 1 diabetes. Sci Transl Med, 9, 2017 eaaf7779.
37. Bonifacio, E, Ziegler, AG, Klingensmith, G, et al. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial. JAMA 313 (2015), 1541–1549.
38. Roep, BO, Solvason, N, Gottlieb, PA, et al. Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8+ T cells in type 1 diabetes. Sci Transl Med, 5, 2013, 191ra82.
39. Ludvigsson, J, Krisky, D, Casas, R, et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 366 (2012), 433–442.
40. Wherrett, DK, Bundy, B, Becker, DJ, et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 378 (2011), 319–327.
41. Vehik, K, Cuthbertson, D, Ruhlig, H, et al. Long-term outcome of individuals treated with oral insulin: Diabetes Prevention Trial–Type 1 (DPT-1) oral insulin trial. Diabetes Care 34 (2011), 1585–1590.
42. Fourlanos, S, Perry, C, Gellert, SA, et al. Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes. Diabetes 60 (2011), 1237–1245.
43. Walter, M, Philotheou, A, Bonnici, F, Ziegler, AG, Jimenez, R, NBI-6024 Study Group. No effect of the altered peptide ligand NBI-6024 on β-cell residual function and insulin needs in new-onset type 1 diabetes. Diabetes Care 32 (2009), 2036–2040.
44. Orban, T, Farkas, K, Jalahej, H, et al. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun 34 (2010), 408–415.
45. Thrower, SL, James, L, Hall, W, et al. Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man phase I safety study. Clin Exp Immunol 155 (2009), 156–165.
46. Agardh, CD, Lynch, KF, Palmer, M, Link, K, Lernmark, A, GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes. Diabetologia 52 (2009), 1363–1368.
47. Vandemeulebroucke, E, Gorus, FK, Decochez, K, et al. Insulin treatment in IA-2A-positive relatives of type 1 diabetic patients. Diabetes Metab 35 (2009), 319–327.
48. Nanto-Salonen, K, Kupila, A, Simell, S, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 372 (2008), 1746–1755.
49. Maruyama, T, Tanaka, S, Shimada, A, et al. Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus. J Clin Endocrinol Metab 93 (2008), 2115–2121.
50. Ludvigsson, J, Faresjo, M, Hjorth, M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 359 (2008), 1909–1920.
51. Schloot, NC, Meierhoff, G, Lengyel, C, et al. Effect of heat shock protein peptide DiaPep277 on β-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials. Diabetes Metab Res Rev 23 (2007), 276–285.
52. Raz, I, Avron, A, Tamir, M, et al. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial. Diabetes Metab Res Rev 23 (2007), 292–298.
53. Lazar, L, Ofan, R, Weintrob, N, et al. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study. Diabetes Metab Res Rev 23 (2007), 286–291.
54. Huurman, VA, Decochez, K, Mathieu, C, Cohen, IR, Roep, BO, Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev 23 (2007), 269–275.
55. Sosenko, JM, Skyler, JS, Beam, CA, et al. The acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in Diabetes Prevention Trial–Type 1 participants. Diabetes 62 (2013), 4179–4183.
56. Greenbaum, CJ, Beam, CA, Boulware, D, et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 61 (2012), 2066–2073.
57. Ferrannini, E, Mari, A, Nofrate, V, Sosenko, JM, Skyler, JS, Group DPT-1 Study Group. Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset. Diabetes 59 (2010), 679–685.
58. Daniel, D, Wegmann, D, Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9–23). Proc Natl Acad Sci USA 93 (1996), 956–960.
59. Zhang, J, Davidson, L, Eisenbarth, GS, Weiner, H, Suppression of diabetes in non-obese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci USA 88 (1991), 10252–10256.
60. Achenbach, P, Koczwara, K, Knopff, A, Naserke, H, Ziegler, AG, Bonifacio, E, Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest 114 (2004), 589–597.
61. Skyler, JS, Krischer, JP, Wolfsdorf, J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial–Type 1. Diabetes Care 28 (2005), 1068–1076.
62. von Herrath, M, Peakman, M, Roep, B, Progress in immune-based therapies for type 1 diabetes. Clin Exp Immunol 172 (2013), 186–202.
63. Peakman, M, Dayan, CM, Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire?. Immunology 104 (2001), 361–366.
64. Huurman, VA, Hilbrands, R, Pinkse, GG, et al. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS One, 3, 2008, e2435.
65. Raz, I, Elias, D, Avron, A, Tamir, M, Metzger, M, Cohen, IR, β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double- blind, phase II trial. Lancet 358 (2001), 1749–1753.
66. Gibson, VB, Nikolic, T, Pearce, VQ, Demengeot, J, Roep, BO, Peakman, M, Proinsulin multi-peptide immunotherapy induces antigen-specific regulatory T cells and limits autoimmunity in a humanized model. Clin Exp Immunol 182 (2015), 251–260.
67. Beringer, DX, Kleijwegt, FS, Wiede, F, et al. T cell receptor reversed polarity recognition of a self-antigen major histocompatibility complex. Nat Immunol 16 (2015), 1153–1161.
68. Kleijwegt, FS, Laban, S, Duinkerken, G, et al. Critical role for TNF in the induction of human antigen-specific regulatory T cells by tolerogenic dendritic cells. J Immunol 185 (2010), 1412–1418.
69. 3 or dexamethasone: differential role for PD-L1. Eur J Immunol 39 (2009), 3147–3159.
70. Clemente-Casares, X, Blanco, J, Ambalavanan, P, et al. Expanding antigen-specific regulatory networks to treat autoimmunity. Nature 530 (2016), 434–440.
71. Sims, EK, Chaudhry, Z, Watkins, R, et al. Elevations in the fasting serum proinsulin-to-C-peptide ratio precede the onset of type 1 diabetes. Diabetes Care 39 (2016), 1519–1526.
72. Tree, TI, Lawson, J, Edwards, H, et al. Naturally arising human CD4 T-cells that recognize islet autoantigens and secrete interleukin-10 regulate proinflammatory T-cell responses via linked suppression. Diabetes 59 (2010), 1451–1460.
73. Arif, S, Tree, TI, Astill, TP, et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 113 (2004), 451–463.
74. Petrich de Marquesini, LG, Fu, J, Connor, KJ, et al. IFN-γ and IL-10 islet-antigen-specific T cell responses in autoantibody-negative first-degree relatives of patients with type 1 diabetes. Diabetologia 53 (2010), 1451–1460.
75. Thompson, WS, Pekalski, ML, Simons, HZ, et al. Multi-parametric flow cytometric and genetic investigation of the peripheral B cell compartment in human type 1 diabetes. Clin Exp Immunol 177 (2014), 571–585.
76. Beam, CA, MacCallum, C, Herold, KC, et al. GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis. Diabetologia 60 (2017), 43–49.
77. van Lummel, M, Duinkerken, G, van Veelen, PA, et al. Posttranslational modification of HLA-DQ binding islet autoantigens in type 1 diabetes. Diabetes 63 (2014), 237–247.
78. Delong, T, Wiles, TA, Baker, RL, et al. Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science 351 (2016), 711–714.
79. Pathiraja, V, Kuehlich, JP, Campbell, PD, et al. Proinsulin-specific, HLA-DQ8, and HLA-DQ8-transdimer-restricted CD4+ T cells infiltrate islets in type 1 diabetes. Diabetes 64 (2015), 172–182.
80. Mannering, SI, Harrison, LC, Williamson, NA, et al. The insulin A-chain epitope recognized by human T cells is posttranslationally modified. J Exp Med 202 (2005), 1191–1197.
81. van Lummel, M, van Veelen, PA, de Ru, AH, et al. Discovery of a selective islet peptidome presented by the highest-risk HLA-DQ8trans molecule. Diabetes 65 (2015), 732–741.
82. van Lummel, M, van Veelen, PA, Zaldumbide, A, et al. Type 1 diabetes-associated HLA-DQ8 transdimer accommodates a unique peptide repertoire. J Biol Chem 287 (2012), 9514–9524.
83. Roep, BO, Kracht, MJ, van Lummel, M, Zaldumbide, A, A roadmap of the generation of neoantigens as targets of the immune system in type 1 diabetes. Curr Opin Immunol 43 (2016), 67–73.
84. Kracht, MJL, van Lummel, M, Nikolic, T, et al. Autoimmunity against a defective ribosomal insulin gene product in type 1 diabetes. Nat Med 23 (2017), 501–507.
85. Kracht, MJ, Zaldumbide, A, Roep, BO, Neoantigens and microenvironment in type 1 diabetes: lessons from antitumor immunity. Trends Endocrinol Metab 27 (2016), 353–362.
86. Harbige, J, Eichmann, M, Peakman, M, New insights into non-conventional epitopes as T cell targets: the missing link for breaking immune tolerance in autoimmune disease?. J Autoimmun 84 (2017), 12–20.
87. Diabetes Prevention Trial–Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 346 (2002), 1685–1691.
88. Woittiez, NJ, Roep, BO, Impact of disease heterogeneity on treatment efficacy of immunotherapy in type 1 diabetes: different shades of gray. Immunotherapy 7 (2015), 163–174.
89. Kappos, L, Comi, G, Panitch, H, et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nat Med 6 (2000), 1176–1182.
90. Bresson, D, Togher, L, Rodrigo, E, et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest 116 (2006), 1371–1381.
91. Takiishi, T, Korf, H, Van Belle, TL, et al. Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J Clin Invest 122 (2012), 1717–1725.
92. Maazi, H, Shirinbak, S, den Boef, LE, et al. Cytotoxic T lymphocyte antigen 4-immunoglobulin G is a potent adjuvant for experimental allergen immunotherapy. Clin Exp Immunol 172 (2013), 113–120.
93. Orban, T, Beam, CA, Xu, P, et al. Reduction in CD4 central memory T-cell subset in costimulation modulator abatacept-treated patients with recent-onset type 1 diabetes is associated with slower C-peptide decline. Diabetes 63 (2014), 3449–3457.
94. Long, SA, Rieck, M, Sanda, S, et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes 61 (2012), 2340–2348.